Reid Merryman

Reid Merryman, MD is an Assistant Professor of Medicine at Harvard Medical School, Boston, MA, USA, and a Senior Physician in the Division of Lymphoma at Dana-Farber Cancer institute (DFCI). He received his undergraduate degree from the University of Notre Dame and his medical degree from Harvard Medical School. He completed residency training in internal medicine at Brigham and Women's Hospital and fellowship training in hematology and oncology at DFCI. He serves as the Director of Clinical Research for the Lymphoma Division and as the Director of the Follicular Lymphoma Center and the Marginal Zone Lymphoma Center at DFCI. His research interests include 1) development of novel immune-based treatments in Hodgkin lymphoma and indolent non-Hodgkin lymphoma (NHL) and 2) identification of novel biomarkers (like circulating tumor DNA) to guide response-adapted treatment approaches. He is currently leading 3 investigator-initiated trials testing CD3/CD20 bispecific antibody-based therapeutic approaches for patients with newly diagnosed or relapsed/refractory indolent NHLs.